- Home
- YJ vs SNGX Comparison
YJ vs SNGX Comparison
Compare YJ & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YJ
- SNGX
- Stock Information
- Founded
- YJ 2015
- SNGX 1987
- Country
- YJ China
- SNGX United States
- Employees
- YJ N/A
- SNGX N/A
- Industry
- YJ Other Specialty Stores
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- YJ Consumer Discretionary
- SNGX Health Care
- Exchange
- YJ Nasdaq
- SNGX Nasdaq
- Market Cap
- YJ 8.8M
- SNGX 7.4M
- IPO Year
- YJ 2019
- SNGX 1987
- Fundamental
- Price
- YJ $1.83
- SNGX $2.43
- Analyst Decision
- YJ
- SNGX
- Analyst Count
- YJ 0
- SNGX 0
- Target Price
- YJ N/A
- SNGX N/A
- AVG Volume (30 Days)
- YJ 26.3K
- SNGX 31.1K
- Earning Date
- YJ 03-20-2025
- SNGX 03-14-2025
- Dividend Yield
- YJ N/A
- SNGX N/A
- EPS Growth
- YJ N/A
- SNGX N/A
- EPS
- YJ N/A
- SNGX N/A
- Revenue
- YJ $66,957,730.00
- SNGX $364,183.00
- Revenue This Year
- YJ N/A
- SNGX N/A
- Revenue Next Year
- YJ N/A
- SNGX $76.64
- P/E Ratio
- YJ N/A
- SNGX N/A
- Revenue Growth
- YJ N/A
- SNGX N/A
- 52 Week Low
- YJ $1.42
- SNGX $1.83
- 52 Week High
- YJ $3.84
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- YJ 54.70
- SNGX 46.06
- Support Level
- YJ $1.65
- SNGX $2.35
- Resistance Level
- YJ $1.75
- SNGX $2.47
- Average True Range (ATR)
- YJ 0.12
- SNGX 0.13
- MACD
- YJ 0.00
- SNGX 0.04
- Stochastic Oscillator
- YJ 54.55
- SNGX 61.36
About YJ Yunji Inc. American Depository Shares
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in China.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).